Co-hosted by China Pharmaceutical Innovation and Research Development Association (herein after referred to as PhIRDA), Eliminate Cancer Initiative (herein after referred to as ECI), National Foundation for Cancer Research (herein after referred to as NFCR) and organized by Beijing Tiantan Hospital of Capital Medical University, China Brain Cancer Mission--Working Group Meeting was successfully held in the new headquarter of Beijing Tiantan Hospital. Over 30 global leaders of pharmaceutical and scientific researches, clinical experts of domestic brain cancer research institutions, senior managers of domestic pharmaceutical innovation enterprises that focusing on therapeutic drugs R&D for brain cancer and partners of pharmaceutical investment institutions participated in this event.
The meeting was chaired by Dr. Li Wenbin, Professor of Capital Medical University, Dr. Wang Yongjun, President of Tiantan Hospital, Mr. Andrew Forrest, Founder and Chairman of ECI and Dr. Sujuan Ba, President and COO of NFCR, CEO and Founder of Asian Fund for Cancer Research (AFCR) delivered opening remarks.
Opening Remarks by VIP Guests
Song Ruilin, Executive President of PhIRDA delivered a keynote speech titled the Prospect for Pharmaceutical Innovation in China and Brain Cancer Drug R&D. In recent years, brain cancer has ranked top 10 in incidence rate in China and drew lots of attention from the government and public. As the exchanges and cooperation between China and the world in the field of brain cancer research continue to deepen, research on brain cancer and its therapeutic drugs will also be advanced by leaps and bounds. China together with colleagues around the world will jointly straggle against brain cancer.
Mr. Song Ruilin, Executive President of PhIRDA delivered a keynote speech
Li Jinju, Deputy Director of the Department of Drug and Cosmetics of State Drug Administration (SDA), and Jiang Tao, Professor of Tiantan Hospital GBM Center delivered keynote speeches about priority review and approval, extended clinical trials and status of brain cancer environment in China.
Ms. Li Jinju, Deputy Director of the Department of Drug and Cosmetics of SDA delivered a keynote speech
Mr. Jiang Tao, Professor of Tiantan Hospital GBM Center delivered a keynote speech
The participants had a productive discussion on how to establish adaptive clinical trial platforms, promote research through international collaboration, cancer treatment innovation driven by big data and identify potential funding sources and targeted support.
Many consensus was reached at the meeting and all parties would bring joint efforts to set up working groups that focus on fundamental research, clinical trials, Biobank and big data process and funding.
PhIRDA and NFCR would cooperate to establish a clinical drugs research platform for brain cancer in the Beijing Tiantan Hospital of Capital Medical University. We believe that every cancer patient in the world will benefit from the historic development due to the joint efforts of all parties.
Co-hosted by China Pharmaceutical Innovation and Research Development Association (PhIRDA) and Suzhou Industrial Park Administrative Office (SIPAC) and co-organized by Chinese American Hematologist and Oncologist Network (CAHON), SINO-U.S.